15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Alx Oncology Holdings, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $4.00 to $5.00, so the covering firms are broadly aligned. The average target of $4.33 sits 116% above the current $2.01. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.13 next quarter toward $-0.55 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Strong Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Alx Oncology Holdings.
As of Sep, 3 of 3 firms rate ALXO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ALXO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.13
Range $-0.17 – $-0.09 · 6 analysts · -69% YoY
Next period, 6 analysts expect Alx Oncology Holdings to earn $-0.13 a share (range $-0.17 – $-0.09), versus $-0.42 a year earlier. Full-year consensus is $-2.64, growing to $-0.55 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 6 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Alx Oncology Holdings
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ALXO.
#1
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #252
Buy
$4.00+99.0% to target
Overall win rate
38%
+ Follow
#2
Li Watsek
Cantor Fitzgerald · Rank #275
Buy
No targeton ALXO
Overall win rate
36%
+ Follow
#3
Derek Archila
Wells Fargo · Rank #390
Buy
$5.00+148.8% to target
Overall win rate
35%
+ Follow
#4
CB
Colin Bristow
UBS
Buy
$1.00-50.2% to target
Coverage
—
+ Follow
#5
MY
Michael Yee
Jefferies
Buy
$3.00+49.3% to target
Coverage
—
+ Follow
ALXO stock forecast FAQ
What is ALXO's average 12-month price target?+
The 3 analysts with a live target average $4.33 for Alx Oncology Holdings over the next 12 months, ranging from a $5.00 high to a $4.00 low.
Is ALXO stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ALXO?+
The Street-high target is $5.00 (Wells Fargo), and the Street-low is $4.00 (HC Wainwright & Co.). The average of all 3 active targets is $4.33.
How many Wall Street analysts cover ALXO?+
3 analysts have an active rating on Alx Oncology Holdings, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering ALXO?+
Among analysts who currently cover ALXO, Swayampakula Ramakanth of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #252). Their current call is Buy with a $4.00 target.
What is Alx Oncology Holdings's projected EPS for next quarter?+
The consensus estimate is $-0.13 per share (range $-0.17 – $-0.09) across 6 analysts. Full-year EPS is projected at $-2.64, rising to $-0.55 the following year.
How much revenue is Alx Oncology Holdings expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ALXO lately?+
As of Sep, 3 of 3 firms rate ALXO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ALXO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
